These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2906695)

  • 1. Clinical pharmacology of urapidil.
    Prichard BN; Renondin JC; Tomlinson B
    J Hypertens Suppl; 1988 Dec; 6(2):S13-9. PubMed ID: 2906695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urapidil, a multiple-action alpha-blocking drug.
    Prichard BN; Tomlinson B; Renondin JC
    Am J Cardiol; 1989 Aug; 64(7):11D-15D. PubMed ID: 2569263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of reflex tachycardia by central administration of the alpha-1 adrenoceptor antagonists urapidil and prazosin in anesthetized dogs.
    Shebuski RJ; Zimmerman BG
    J Pharmacol Exp Ther; 1985 Aug; 234(2):456-62. PubMed ID: 2862276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular effects of urapidil].
    Bousquet P; Decker N; Feldman J; Schwartz J
    J Pharmacol; 1983; 14(4):465-72. PubMed ID: 6672466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic haemodynamic and humoral changes during urapidil treatment in hypertensive patients.
    Leonetti G; Terzoli L; Zanchetti A
    J Hypertens Suppl; 1988 Dec; 6(2):S25-9. PubMed ID: 2906697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha adrenergic blocking activity of urapidil in man.
    Jamieson MJ; Shepherd AM; Jackson SH; Patel SS; Flanagan PH; Galbraith H
    Res Commun Chem Pathol Pharmacol; 1988 Nov; 62(2):173-85. PubMed ID: 2908008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of urapidil in the treatment of acute hypertension].
    Lehot JJ; Bonnefoy E; Dalmas JP; Filley S; Bastien O; George M
    Cah Anesthesiol; 1995; 43(1):67-76. PubMed ID: 7671060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacologic profile of urapidil. Consequences for use as an antihypertensive drug].
    van Zwieten PA
    Fortschr Med; 1992 Jun; 110(17):330-2. PubMed ID: 1353745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the mechanism of the hypotensive action of urapidil.
    Bousquet P; Feldman J; Schwartz J
    J Hypertens Suppl; 1985 Dec; 3(3):S187-9. PubMed ID: 2856701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of food intake on the bioavailability of urapidil in healthy volunteers.
    Kirsten R; Nelson K; Molz KH; Gielsdorf W; Haerlin R
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):298-301. PubMed ID: 2737799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dopamine on renal haemodynamics tubular function and sodium excretion in normal humans.
    Olsen NV
    Dan Med Bull; 1998 Jun; 45(3):282-97. PubMed ID: 9675540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of urapidil and nitroprusside on hemodynamics and myocardial function in hypertension following cardiac surgery.
    Van der Stroom JG; Van Wezel HB; Koolen JJ; Visser CA; Van Zwieten PA
    Blood Press Suppl; 1994; 4():31-8. PubMed ID: 7804510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046.
    Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD
    Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of urapidil on blood pressure and adrenoceptors in various animal models.
    van Zwieten PA; Mathy MJ; Thoolent MJ; Wilffert B; de Jonge A; Timmermans PB
    J Hypertens Suppl; 1984 Dec; 2(3):S539-41. PubMed ID: 6599713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of urapidil on responses to phenylephrine, angiotensin and isoprenaline in man.
    Tomlinson B; Renondin JC; Graham BR; Prichard BN
    Eur J Clin Pharmacol; 1991; 41(1):1-3. PubMed ID: 1685992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypotensive effect of urapidil: CNS site and relative contribution.
    Gillis RA; Dretchen KL; Namath I; Anastasi N; Dias Souza J; Hill K; Browne RK; Quest JA
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):103-9. PubMed ID: 2434784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of urapidil on cardiac alpha- and beta-adrenoceptors.
    Schümann HJ; Bielefeld FW
    Arzneimittelforschung; 1986 Oct; 36(10):1471-6. PubMed ID: 3028433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of urapidil with brain serotonin-1A receptors increases the blood pressure reduction due to peripheral alpha-adrenoceptor inhibition.
    Sanders KH; Beller KD; Bischler P; Kolassa N
    J Hypertens Suppl; 1988 Dec; 6(2):S65-8. PubMed ID: 2906703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.